Product Details

And the US Winners Are… GSK, Lilly and Pfizer

US investigative sites place GlaxoSmithKline, Eli Lilly, and Pfizer among the top companies with which to work, based on the results of the new 2003 CenterWatch survey. With the exception of Eli Lilly, most of the more than 30 companies evaluated have been unsuccessful at significantly improving the mediocre quality of their site relationships over 2001 levels.

Missed Opportunities with Site Initiation Visits

Site initiation visits are considered largely ineffective by investigative sites due to both time and resource constraints. Yet sites and sponsors widely acknowledge the value and importance of maximizing face time during initiation visits to discuss study protocols and project-specific issues. Select sponsors and sites are experimenting with new approaches to optimize the value of site initiation visits. Improved site visit effectiveness is driving more efficient and higher quality study conduct performance.

Also in this issue:

• European Biotech Lacking a Boost from Major Sponsors and CROs
• Eye on: Hyperlipidemia